antianginaldrugs抗心绞痛药-ppt课件-精品_第1页
antianginaldrugs抗心绞痛药-ppt课件-精品_第2页
antianginaldrugs抗心绞痛药-ppt课件-精品_第3页
antianginaldrugs抗心绞痛药-ppt课件-精品_第4页
antianginaldrugs抗心绞痛药-ppt课件-精品_第5页
已阅读5页,还剩25页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Part 6 Antianginal Drugs Organic nitrates receptor blockers Calcium channel blockersCoronary vessels: blood supply for the heart1. OVERVIEWCoronary atherosclerosis: cause of cardiac ischemiaDistribution of coronary arteries in the heartIschemia (angina pectoris ): imbalance between oxygen demand and

2、 supplyClassification of angina pectoris:Exertional angina (劳累性心绞痛) Stable angina (稳定性心绞痛) Initial onset angina (初发型心绞痛) Accelerated angina (恶化性心绞痛)Spontaneous angina (自发性心绞痛) Angina decubitus (卧位型心绞痛) Variant or vasospastic angina (变异性痉挛性心绞痛) Acute coronary insufficiency (急性冠脉功能不全) Postinfarction a

3、ngina (梗死后心绞痛)Mixed angina (混合性心绞痛) Unstable angina (不稳定性心绞痛)1. OVERVIEWMyocardial oxygen demand is chiefly determined by: Contractility Heart rate Wall tension Preload (venous return ) Afterload (arteriolar resistance) 1. OVERVIEWpreloadafterloadMyocardial oxygen demand is diminished by: Reducing c

4、ontractility Reducing heart rate Reducing the preload Reducing the afterload1. OVERVIEWWall tension 1. OVERVIEWMyocardial oxygen supply is chiefly determined by: AV oxygen difference Regional myocardial distribution coronary blood flow: vascular resistance, artery pressure Effects of antianginal dru

5、gs:Reducing oxygen demands Reducing heart rate and contractility Dilating systemic arteries and veins ( wall tension by lowering heart loads)Increasing oxygen supply Dilating conduct coronary arteries ( coronary blood flow) Promoting regional distribution ( in ischemic regions)Others: Anti- platelet

6、 coagulation and thrombus formation 1. OVERVIEW2.1 NitratesNitroglycerin (硝酸甘油)A. Pharmacological actions Dilating vessels and reducing heart loads wall tension ; reflex tachycardia Redistribution of coronary circulation dilating conduct artery: collateral circulation reducing wall tension: blood fl

7、ow in ischemic subendocardial area 2. Antianginal drugsInfluence of organic nitrates and dipyridamole on the blood supply of ischemic area2. Antianginal drugsMechanism of the effect of nitroglycerin and other nitrates2. Antianginal drugsMechanism of the effect of nitroglycerin and other nitratesB. C

8、linical uses Angina pectoris: all kinds, especially stable type Heart failure:reducing heart loads due to vasodilationC. Adverse reactions Increase in heart rate and contractility Symptoms due to vasodilation: headache, flash, postural hypotension, collapse, ect. Others: methaemoglobinaemia(高铁血红蛋白)

9、Tolerance : avoiding steady-state plasma concentration; supplement of agents containing SH (captopril) 2. Antianginal drugs2.1 Other nitrates Isosorbide dinitrate (硝酸异山梨酯) Isosorbide-5-mononirate (5-硝酸异山梨酯) Compared with nitroglycerin: Similar but weaker effect Acting slowly but lasting longer Large

10、r individual variation and more adverse effects2. Antianginal drugs2.2 receptor blockersA. Pharmacological action Reducing oxygen demand: heart rate and contractility Increasing oxygen supply: diastolic period : perfusion time vascular tone in normal regions : blood flow in ischemic regions Others:

11、Improving myocardial metabolism Inhibiting coagulation of platelets2. Antianginal drugsB. Clinical uses stable and unstable pectoris, especially associated with hypertension or arrhythmias, even with myocardial infarction; but not used for variant angina pectorisC. Notes Dose individualization: star

12、ting from small dose Withdraw gradually and slowly: symptom rebound Combination with nitroglycerin2. Antianginal drugs2.3 Calcium channel blockers2. Antianginal drugs2.3 Calcium channel blockersA. Pharmacological actions Reducing myocardial oxygen remand: heart loads : nifedipine heart rate and cont

13、ractility : verapamil and diltiazem Increasing myocardial blood supply Protecting ischemic myocardial cells Inhibiting coagulation of platelets2. Antianginal drugsActions of calcium channel blockersB. Clinical uses stable and variant type: nifedipine, verapamil, diltiazem unstable type: verapamil, d

14、iltiazem2. Antianginal drugsActions of DHP (like nifedipine) are similar to those of nitroglycerinActions of verapamil and diltiazem are similar to those of blockers2.4 Other drugsACEIs (血管紧张素转化酶抑制药)Treating hypertension and preventing ischemic heart disease Reducing heart loadsInhibiting cardial re

15、modeling Nicorandil (尼可地尔) Opening ATP-sensitive K+ channel (KATP) Lowering intracellular Ca2+ Providing NO (like nitroglycerin)Inducing ischemic preconditioning 2. Antianginal drugsMolsidomine (吗多明)Inhibiting adenosine uptake and cAMP degradation Inhibiting pletelet aggregationPromoting collateral

16、circulation after long-term useDipyridamole (双嘧达莫,潘生丁) Inhibiting adenosine uptake and cAMP degradation Inhibiting pletelet aggregationPromoting collateral circulation after long-term use2. Antianginal drugs nitroglycerin blockers Ca2+ antagonists combination*Heart rate Contractility /Wall tension /

17、 /Oxygen demand Blood pressure : increase, : markedly increase; : decrease, : markedly decrease; : variable according to the dose and effect of each drug ; * blockers combined with nitroglycerin or Ca2+ antagonists (nifedipine; combination with verapamil/diltiazem not be recommendated)Caution: Combi

18、nation may potentiate the antianginal effects, but may induce severe hypotension3. Summary of antianginal drugsSammaryCardiovascular pharmacologyOverview of Cardiovascular DiseasesCommon Cardiac DiseasesAbnormal contractility:Heart failuresAbnormal rhythms:ArrhythmiasAbnormal blood supply:Ischemic h

19、eart diseases Myocardial disordersCommon vascular diseasesAbnormal systematic resistance:HypertensionDysfunction of coronary vessels:Coronary vascular diseasesDysfunction of cerebral vessels:Cerebral ischemia, hemorrhageDysfunction of pulmonary vessels:Pulmonary hypertensionDysfunction of peripheral vessels: Peripheral vascular disorderArteriosclerosis: basis of most CVS diseasesOverview of Cardiovascular Drugs Classification based on target organs/tissues

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论